NCT02845804Unknown不适用
Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 1,533
- 试验地点
- 20
- 主要终点
- Target lesion failure
研究概览
简要总结
The objectives of this study are
- To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent
- To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent
- To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry
详细描述
Secondary endpoints of this study are
Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI
Target vessl failure
Composite rate of cardiac death and any MI, 3 years
Composite rate of all death and any MI
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient agrees to participate in this study by signing the informed consent form.
- •Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form
排除标准
- •There are no exclusion criteria for this registry.
结局指标
主要结局
Target lesion failure
时间窗: 12 months
Composite of cardiac death, non-fatal target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)
次要结局
- Target vessel failure(12 months)
- Composite rate of cardiac death and myocardial infarction(12 months, 3 years)
- Composite rate of all-cause death and any myocardial infarction(12 months, 3 years)
- Composite rate of all-cause death and any myocardial infarction, and any repeat revascularization(12 months, 3 years)
- Rate of compliance and interruptions with prescribed adjunctive antiplatelet therapy(12 months, 3 years)
- Clinical device and procedural success rate(intraoperative)
- Stent thrombosis(within 24 hours, 1 - 30 days, 31 days - 1 year, after 1 year)
研究者
Hyo-Soo Kim
Professor
Seoul National University Hospital
研究点 (20)
Loading locations...
相似试验
Unknown
不适用
Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary AtherosclerosisMyocardial InfarctionAcute Coronary SyndromeCoronary Artery DiseaseAngina PectorisNCT03151018Seoul National University Hospital4,000
Unknown
不适用
Observational Registry on Clinical Outcome After Diagnosis of Chronic Total OcclusionsAngina PectorisChronic Total Occlusion of Coronary ArteryNCT04145167Ziekenhuis Netwerk Antwerpen (ZNA)400
终止
不适用
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)Indolent Non Hodgkin's Lymphoma (iNHL)Chronic Lymphocytic Leukaemia (CLL)NCT02273856Astellas Pharma International B.V.25
已完成
不适用
Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric PopulationAppendix MassAppendicitis PerforatedAppendicitisNCT04755179Ramon Gorter1,308
已完成
不适用
Prevention and Treatment of Laryngospasm and Hypoxemia Based on Risk Factors in Adult Outpatients Undergoing EGDHypoxemiaLaryngospasmNCT04159116Envision Healthcare Scientific Intelligence, Inc.57